Selective inhibition of IDO1 effectively regulates mediators of antitumor immunity.
暂无分享,去创建一个
Qian Wang | Beth Thomas | Richard Wynn | Mark Rupar | R. Wynn | J. Fridman | H. Koblish | P. Scherle | T. Burn | L. Leffet | Yanlong Li | P. Waeltz | M. Rupar | M. Hansbury | Kevin J. Bowman | Gengjie Yang | R. Sparks | E. Yue | A. Combs | Padmaja Polam | Xiangdong Liu | R. Newton | Robert C Newton | Jordan S Fridman | Holly K Koblish | Peggy A Scherle | Eddy W Yue | Andrew P Combs | Qian Wang | Xiangdong Liu | Gengjie Yang | Padmaja Polam | Yanlong Li | Timothy C Burn | Niu Shin | Kathy Wang | Lynn Leffet | Michael J Hansbury | Paul Waeltz | Kevin J Bowman | Richard B Sparks | N. Shin | K. Wang | B. Thomas
[1] Jun Du,et al. Prevention of spontaneous tumor development in a ret transgenic mouse model by ret peptide vaccination with indoleamine 2,3-dioxygenase inhibitor 1-methyl tryptophan. , 2009, Cancer research.
[2] D. Munn,et al. A high‐affinity, tryptophan‐selective amino acid transport system in human macrophages , 2006, Journal of leukocyte biology.
[3] L. Moretta,et al. The tryptophan catabolite L-kynurenine inhibits the surface expression of NKp46- and NKG2D-activating receptors and regulates NK-cell function. , 2006, Blood.
[4] S. Agaugué,et al. 1-Methyl-Tryptophan Can Interfere with TLR Signaling in Dendritic Cells Independently of IDO Activity1 , 2006, The Journal of Immunology.
[5] Hans-Georg Rammensee,et al. IDO1 and IDO2 are expressed in human tumors: levo- but not dextro-1-methyl tryptophan inhibits tryptophan catabolism , 2008, Cancer Immunology, Immunotherapy.
[6] I. Alexander,et al. HeLa cells cocultured with peripheral blood lymphocytes acquire an immuno‐inhibitory phenotype through up‐regulation of indoleamine 2,3‐dioxygenase activity , 2002, Immunology.
[7] Weiping Zou,et al. Immunosuppressive networks in the tumour environment and their therapeutic relevance , 2005, Nature Reviews Cancer.
[8] Jun Du,et al. Enhancement of dendritic cell-tumor fusion vaccine potency by indoleamine-pyrrole 2,3-dioxygenase inhibitor, 1-MT , 2008, Journal of Cancer Research and Clinical Oncology.
[9] D. Fuchs,et al. Decreased Serum Tryptophan Concentration Predicts Poor Prognosis in Malignant Melanoma Patients , 2006, Dermatology.
[10] James E. Thompson and. Photochemical Preparation of a Pyridone Containing Tetracycle: A Jak Protein Kinase Inhibitor. , 2010 .
[11] H. Ball,et al. Indoleamine 2,3-dioxygenase-2; a new enzyme in the kynurenine pathway. , 2009, The international journal of biochemistry & cell biology.
[12] G. Prendergast,et al. Inhibition of indoleamine 2,3-dioxygenase in dendritic cells by stereoisomers of 1-methyl-tryptophan correlates with antitumor responses. , 2007, Cancer research.
[13] J. Fridman,et al. Selective inhibition of ADAM metalloproteases blocks HER-2 extracellular domain (ECD) cleavage and potentiates the anti-tumor effects of trastuzumab , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[14] J. Fridman,et al. Hydroxyamidine Inhibitors of Indoleamine-2,3-dioxygenase Potently Suppress Systemic Tryptophan Catabolism and the Growth of IDO-Expressing Tumors , 2010, Molecular Cancer Therapeutics.
[15] D. Sansom,et al. What's the difference between CD80 and CD86? , 2003, Trends in immunology.
[16] W. Zou. Regulatory T cells, tumour immunity and immunotherapy , 2006, Nature Reviews Immunology.
[17] G. Prendergast,et al. Inhibition of indoleamine 2,3-dioxygenase, an immunoregulatory target of the cancer suppression gene Bin1, potentiates cancer chemotherapy , 2005, Nature Medicine.
[18] D. Fuchs,et al. Serum tryptophan decrease correlates with immune activation and impaired quality of life in colorectal cancer , 2002, British Journal of Cancer.
[19] F. Hirata,et al. Indoleamine 2,3-dioxygenase. Purification and some properties. , 1978, The Journal of biological chemistry.
[20] B. Baban,et al. Cutting Edge: Induced Indoleamine 2,3 Dioxygenase Expression in Dendritic Cell Subsets Suppresses T Cell Clonal Expansion1 , 2003, The Journal of Immunology.
[21] G. Prendergast,et al. Chronic inflammation that facilitates tumor progression creates local immune suppression by inducing indoleamine 2,3 dioxygenase , 2008, Proceedings of the National Academy of Sciences.
[22] L. Jermiin,et al. Characterization of an indoleamine 2,3-dioxygenase-like protein found in humans and mice. , 2007, Gene.
[23] O. Hayaishi,et al. Enzymic formation of D-kynurenine from D-tryptophan. , 1967, Archives of biochemistry and biophysics.
[24] V. Duronio,et al. Differential immunosuppressive effect of indoleamine 2,3-dioxygenase (IDO) on primary human CD4+ and CD8+ T cells , 2008, Molecular and Cellular Biochemistry.
[25] U. Grohmann,et al. The Combined Effects of Tryptophan Starvation and Tryptophan Catabolites Down-Regulate T Cell Receptor ζ-Chain and Induce a Regulatory Phenotype in Naive T Cells1 , 2006, The Journal of Immunology.
[26] H. Rammensee,et al. Levo- but not dextro-1-methyl tryptophan abrogates the IDO activity of human dendritic cells. , 2008, Blood.
[27] D. Munn,et al. Indoleamine 2,3‐dioxygenase contributes to tumor cell evasion of T cell‐mediated rejection , 2002, International journal of cancer.
[28] H. Kajiyama,et al. Indoleamine 2,3-dioxygenase is a novel prognostic indicator for endometrial cancer , 2006, British Journal of Cancer.
[29] Milton W. Taylor,et al. Indoleamine 2,3-Dioxygenase Production by Human Dendritic Cells Results in the Inhibition of T Cell Proliferation , 2000, The Journal of Immunology.
[30] L. Mastracci,et al. Eosinophil granulocytes account for indoleamine 2,3-dioxygenase-mediated immune escape in human non-small cell lung cancer. , 2005, Neoplasia.
[31] Stefan Schneeberger,et al. Prognostic value of indoleamine 2,3-dioxygenase expression in colorectal cancer: effect on tumor-infiltrating T cells. , 2006, Clinical cancer research : an official journal of the American Association for Cancer Research.
[32] M. Lai,et al. A Novel Cancer Therapy by Skin Delivery of Indoleamine 2,3-Dioxygenase siRNA , 2009, Clinical Cancer Research.
[33] P. Wallace,et al. Efficacy of levo-1-methyl tryptophan and dextro-1-methyl tryptophan in reversing indoleamine-2,3-dioxygenase-mediated arrest of T-cell proliferation in human epithelial ovarian cancer. , 2009, Cancer research.
[34] P. Bruggen,et al. Human tumor antigens recognized by T lymphocytes , 1996, The Journal of experimental medicine.
[35] Jun Sik Lee,et al. Differential regulation of indoleamine 2,3‐dioxygenase by lipopolysaccharide and interferon gamma in murine bone marrow derived dendritic cells , 2007, FEBS letters.
[36] Z. Trajanoski,et al. Type, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical Outcome , 2006, Science.
[37] Qian Wang,et al. Discovery of potent competitive inhibitors of indoleamine 2,3-dioxygenase with in vivo pharmacodynamic activity and efficacy in a mouse melanoma model. , 2009, Journal of medicinal chemistry.
[38] H. Rammensee,et al. Inhibitors of indoleamine-2,3-dioxygenase for cancer therapy: can we see the wood for the trees? , 2009, Nature Reviews Cancer.
[39] C. Yeo,et al. Expression of indoleamine 2,3-dioxygenase in metastatic pancreatic ductal adenocarcinoma recruits regulatory T cells to avoid immune detection. , 2008, Journal of the American College of Surgeons.
[40] B. Quesnel,et al. Indoleamine 2,3-dioxygenase activity of acute myeloid leukemia cells can be measured from patients' sera by HPLC and is inducible by IFN-gamma. , 2009, Leukemia research.
[41] D. Munn,et al. Ido expression by dendritic cells: tolerance and tryptophan catabolism , 2004, Nature Reviews Immunology.
[42] M. Baccarani,et al. Modulation of tryptophan catabolism by human leukemic cells results in the conversion of CD25- into CD25+ T regulatory cells. , 2007, Blood.
[43] N. Yanaihara,et al. Indoleamine 2,3-Dioxygenase Serves as a Marker of Poor Prognosis in Gene Expression Profiles of Serous Ovarian Cancer Cells , 2005, Clinical Cancer Research.
[44] G. Prendergast,et al. Novel tryptophan catabolic enzyme IDO2 is the preferred biochemical target of the antitumor indoleamine 2,3-dioxygenase inhibitory compound D-1-methyl-tryptophan. , 2007, Cancer research.
[45] D. Munn,et al. Inhibition of T Cell Proliferation by Macrophage Tryptophan Catabolism , 1999, The Journal of experimental medicine.
[46] David J. Freeman,et al. Reinstalling Antitumor Immunity by Inhibiting Tumor-Derived Immunosuppressive Molecule IDO through RNA Interference1 , 2006, The Journal of Immunology.
[47] T. Shima,et al. Expression of indoleamine 2, 3‐dioxygenase and the recruitment of Foxp3‐expressing regulatory T cells in the development and progression of uterine cervical cancer , 2007, Cancer science.
[48] D. Munn,et al. Prevention of allogeneic fetal rejection by tryptophan catabolism. , 1998, Science.
[49] W. Feeser,et al. Anergic T cells are defective in both jun NH2-terminal kinase and mitogen-activated protein kinase signaling pathways , 1996, The Journal of experimental medicine.
[50] C. Uyttenhove,et al. Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase , 2003, Nature Medicine.
[51] E. Jaffee,et al. Recruitment of latent pools of high-avidity CD8+ T cells to the antitumor immune response , 2005, The Journal of experimental medicine.